Reports Q4 revenue $ $27.87M consensus $23.5M…”2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and ...

Earnings per share (EPS) missed analyst estimates by 71%. In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales ...

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing ...